Is there a link between oral minoxidil and pericardial effusion?
A study published in the Journal of Cosmetic Dermatology investigated whether there is an association between the use of oral minoxidil (OM) and pericardial effusion (PE). The investigators included 2,747 reports on OM use, of which 35 reported adverse events were PE. Patients with PE had a mean age of 60 years. A significantly higher proportion of men (89%) was observed in OM reports of PE compared with OM reports of all other AEs (65%). The authors concluded that there was no significant relationship observed between dose of OM and adverse events, including both PE and all other adverse events.
Consensus guidelines for off-label use of oral minoxidil for hair loss. Read more.
DermWorld Insights and Inquiries: Giving a NOD2 to Yao syndrome
Systemic autoinflammatory disorders (SAIDs) are characterized by recurrent attacks of fever, cutaneous signs, chest or abdominal pain, lymphadenopathy, vasculopathy, and musculoskeletal symptoms. In 2011, Yao et al. described a “new” SAID associated with nucleotide-binding oligomerization domain 2 (NOD2) gene mutations. This is now known as Yao syndrome. The number of cases of Yao syndrome due to mutations in NOD2 has been increasing. It should be in the differential diagnosis of patients manifesting recurrent fever, rashes, musculoskeletal, gastrointestinal, and sicca-like symptoms. Keep reading!
Higher cumulative dose of isotretinoin tied to lower acne relapse rate
An article published in JAMA Dermatology explored the characteristics and factors associated with relapse after isotretinoin treatment for acne. The authors evaluated claims from nearly 20,000 patients who had used isotretinoin for at least four months to determine if they had a relapse in acne in the year after treatment. Of the patients included, 22.5% experienced acne relapse.
There was a significant association between cumulative dosage and a lower rate of acne relapse among patients in the low cumulative dosage group, as well as a lower rate of isotretinoin retrial in the low and conventional groups. However, neither association was found among patients in the high cumulative dosage group. According to the authors, patients who prioritize acne clearance without relapse may choose to use higher cumulative doses, whereas patients who are prone to experiencing adverse events and would like to minimize those risks should be treated with lower doses.
A study published in JAMA Dermatology evaluated the efficacy and safety of roflumilast cream vs. vehicle cream in patients with atopic dermatitis (AD). Patients six years or older were randomized 2:1 to receive roflumilast, 0.15%, or vehicle cream once daily for four weeks. Among 1,337 patients, significantly more patients treated with roflumilast achieved the primary end point. At week four, statistically significant differences favoring roflumilast also occurred for the achievement of at least 75% reduction in the Eczema Area and Severity Index. Roflumilast was well tolerated with low rates of adverse events.
AI-enabled hand sensor may reduce nocturnal scratching
In a study published in JAMA Dermatology, researchers explored whether haptic feedback on an AI-enabled wearable device decreased nocturnal scratching in patients with mild atopic dermatitis. The researchers validated the “performance of real-time scratch detection and haptic feedback” by having participants scratch at five common atopic dermatitis locations — the dorsal hand, cheek, neck, inner elbow, and posterior knee — while wearing the sensor on their dorsal hand.
In this cohort study including 10 patients, haptic feedback decreased scratch time (nightly and per hour of sleep opportunity) and scratch events (nightly and per hour of sleep opportunity) by 28% and 50%, respectively, compared with baseline nocturnal scratching behaviors in patients with atopic dermatitis. Overall, patient feedback was positive on the utility of the wearable device.
The FDA issued a warning to TKTX USA regarding the distribution and promotion of unapproved numbing creams used as external analgesics prior to cosmetic procedures, such as tattooing, laser cosmetic procedures, microblading, and others. The products include “TKTX Blue Numbing Cream 40%,” “TKTX Green Numbing Cream 40%,” “TKTX Black Numbing Cream 40%,” “TKTX Gold Numbing Cream 40%,” and “TKTX Yellow Numbing Cream 40%.” The numbing creams include lidocaine concentrations that exceed levels permitted in nonprescription drug products, which could lead to increased absorption through the skin.
Advertisement
The American Academy of Dermatology is a non-profit professional organization and does not endorse companies or products. Advertising helps support our mission.
